Skip to main content

Table 2 Incidence of drug-related adverse events

From: First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers

Drug-related AE# (≥5%) 600 mg bid (N = 14) 800mg bid (N = 6) Total (N = 20)
Grade 1 Grade2 Grade 1 Grade 2 N (%)
Laboratory abnormality  
 Leukopenia 2 1 0 0 3(15.0)
 Neutropenia 2 1 0 0 3(15.0)
 LDH increased 1 0 0 0 1(5.0)
 Thrombocytopenia 1 0 0 0 1(5.0)
Skin and subcutaneous tissue disease
 Rash 0 1 0 0 1(5.0)
Gastrointestinal disorders
 Constipation 0 0 1 0 1(5.0)
 Diarrhea 0 0 0 1 1(5.0)
Serious Adverse Event (SAE)* 600 mg bid 800 mg bid Outcome
Gastrointestinal bleeding 1 1 Resolved/Death
Dyspnea 2 0 Death
Seroperitoneum 1 0 Unresolved
Liver abscess 1 0 Unresolved
Cardiac sudden death 1 0 Death
Liver function damage aggravated 0 1 Death
  1. #No grade 3/4 drug-related AEs were observed
  2. *All SAE were judged by the investigators as drug-unrelated
  3. Abbreviation: LDH: lactate dehydrogenase